Examples of 'ledipasvir' in a sentence
Meaning of "ledipasvir"
Ledipasvir is a noun that refers to a medication used in the treatment of chronic hepatitis C
Show more definitions
- A particular drug for the treatment of hepatitis C.
How to use "ledipasvir" in a sentence
Basic
Advanced
ledipasvir
The active substances are ledipasvir and sofosbuvir.
Ledipasvir had no adverse effects on mating and fertility.
This drug is a combination of ledipasvir and sofosbuvir.
The ledipasvir granules are blended with extragranular lubricant.
No dose adjustment of ledipasvir or sofosbuvir is required.
Ledipasvir solubility decreases as pH increases.
Harvoni contains the active substances ledipasvir and sofosbuvir.
Use with ledipasvir and sofosbuvir.
Both solvents gave rapid dissolution of ledipasvir and copovidone.
Ledipasvir in combination with sofosbuvir forms the necessary complex.
Following is a method for isolating amorphous free base of ledipasvir.
Ledipasvir may be present in the pharmaceutical composition in a therapeutically effective amount.
Animal studies do not indicate harmful effects of ledipasvir or sofosbuvir on fertility.
Medicinal products that increase gastric pH are expected to decrease concentration of ledipasvir.
It is unknown whether ledipasvir or sofosbuvir and its metabolites are excreted in human milk.
See also
These medicines can decrease the amount of ledipasvir in your blood.
The ledipasvir PK profile was altered in the presence of food.
No teratogenic effects were observed in rat and rabbit developmental toxicity studies with ledipasvir.
Harvoni is a medicine that contains the active substances ledipasvir and sofosbuvir in a single tablet.
All trial participants took a new combination pill consisting of the investigational drugs sofosbuvir and ledipasvir.
Solubility of Ledipasvir amorphous free base as a function of pH at room temperature.
Indicates no clinically relevant change in the exposure of Ledipasvir.
See also under Use with ledipasvir and sofosbuvir below.
Furthermore, ledipasvir demonstrated good chemical stability in the ethanolic feed solution.
As such, the combination of sofosbuvir and ledipasvir may be administered without regard to food.
Ledipasvir and sofosbuvir are co-formulated into one tablet that is taken once daily.
The combination of sofosbuvir and ledipasvir has not yet been approved by the FDA.
Previously, ledipasvir had been demonstrated to have a negative food effect when administered alone.
Nizatidine by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of ledipasvir.
See also under Use with ledipasvir and sofosbuvir or sofosbuvir and velpatasvir below.
Antacids by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of ledipasvir.
In one embodiment, the ledipasvir is in the form of a tablet.
Ledipasvir has low aqueous solubility and high permeability, and is considered a BCS Class 2 compound.
In the combination composition, ledipasvir is present in a substantially amorphous form.
The first medication to receive FDA approval was a combination of ledipasvir and sofosbuvir ( Harvoni ).
Concentrations of ledipasvir and simeprevir are increased when simeprevir is co-administered with ledipasvir.
In some embodiments, each dosage unit contains from 3 mg to 2 g of ledipasvir.
The dissolution rate of ledipasvir amorphous free base at pH 3 and 6 was also tested.
In a specific embodiment, the pharmaceutical composition comprises about 9 % w / w of ledipasvir.
Use with ledipasvir and sofosbuvir, sofosbuvir and velpatasvir or sofosbuvir, velpatasvir and voxilaprevir.
Unexpectedly, the combination treatment of ledipasvir and sofosbuvir does not exhibit a negative food effect.
Ledipasvir is a HCV inhibitor targeting the HCV NS5A protein, which is essential for both RNA.
Finally, the sofosbuvir powder blend and ledipasvir powder blend are compressed into bilayer tablet cores.
In a further specific embodiment, the pharmaceutical dosage form comprises about 90 mg of ledipasvir.
Both sofosbuvir and ledipasvir have previously been demonstrated to act as effective anti-HCV agents.
In a specific embodiment, the pharmaceutical composition comprises about 18 % w / w of the solid dispersion of ledipasvir.
NS5A substitutions conferring resistance to ledipasvir may reduce the antiviral activity of other NS5A inhibitors.
Ledipasvir is an inhibitor of the NS5A.
The weight ratio of ledipasvir to polymer is about 1:1.
Ledipasvir is an inhibitor of NS5A, a hepatitis C virus protein.
